Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04002700 · ClinicalTrials.gov registry record
A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group
A clinical trial of Stroke, sponsored by Janssen Research & Development.
- Completed
- Registry status
- 1,234,412
- Enrollment target
- 1
- Study location
NCT04002700: Completed study of Stroke, sponsored by Janssen Research & Development.
NCT04002700 is a study of Stroke that has completed, run by Janssen Research & Development. The registered enrollment target is 1,234,412 participants, above the 9,297-participant average among 454 other Stroke trials with a reported enrollment target (13178% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04002700, a study of Stroke, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- 1,234,412 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and did not have dementia to participants aged 65 years and older regardless of dementia status.
Primary Outcome
Number of participants with stroke in each target cohort versus comparator cohort (aged 65 years and older) per person years at risk will be reported. It is defined defined by the presence of the relevant ICD codes (ICD-9 or ICD-10 according to date) in the inpatient setting as the primary diagnoses.
Conditions Studied
Interventions
- DRUG Haloperidol
- DRUG Typical Antipsychotics
- DRUG Atypical Antipsychotics
Study Locations (1)
New Jersey
- Janssen Investigative Site - Titusville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,234,412 participants |
| Start Date | 2019-05-06 |
| Est. Completion | 2019-05-31 |
What the finished NCT04002700 record still lists
NCT04002700 is an observational study that tracks outcomes without assigning an intervention. Its 1,234,412 participants enrollment target places it among the larger protocols in the corpus, above the 9,297-participant average among 454 other Stroke trials with a reported enrollment target (13178% higher).
The record links to 1 condition, with Stroke appearing as the primary indexed condition, and to 3 interventions - of which Haloperidol is the first listed.
NCT04002700 reports a single indexed study location in New Jersey.
Frequently Asked Questions
What is clinical trial NCT04002700 about?
NCT04002700 is a clinical study titled "A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group". The purpose of this study is to extend the recent Food and Drug Administration (FDA) Sentinel tabulations regarding stroke risk among new users of typical and atypical antipsychotics to participants who were aged 18-64 years and did not have dementia to participants aged 65 years and older regardles...
What is the current status of trial NCT04002700?
This trial is currently completed. The enrollment target is 1,234,412 participants. The study started on 2019-05-06. Estimated completion is 2019-05-31.
What conditions does trial NCT04002700 study?
This clinical trial studies the following conditions: Stroke.
What interventions are being tested in trial NCT04002700?
The interventions under investigation include: Haloperidol (DRUG), Typical Antipsychotics (DRUG), Atypical Antipsychotics (DRUG).
Who is sponsoring clinical trial NCT04002700?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04002700 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04002700's enrollment target sits among peer trials
1,234,412 2nd of 454 the highest of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07022951 · 1,200,000 participants
The Million Anesthesia Cases Study (MACS) - a Cohort Study of Preoperative Fasting and Perioperative Outcomes
- NCT05066763 · 1,000,000 participants
Parkinson's Foundation Surveys
- NCT07075341 · 1,000,000 participants
Healthy Living BEYOND Weight Study
- NCT07224685 · 1,000,000 participants
A Study of Mayo Clinic CV Research Heart & Voice Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI